{
    "nctId": "NCT04692831",
    "briefTitle": "Testing a New Imaging Agent to Identify Cancer",
    "officialTitle": "Imaging of HER2-expressing Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab",
    "overallStatus": "RECRUITING",
    "conditions": "HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Evaluate clinical safety of 89Zr-ss-pertuzumab",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease\n\nNote: HER2 positivity is defined according to American Society of Clinical Oncology guidelines or ERBB2 amplification on next generation sequencing Note: HER2-low is defined as low HER2 expression, with immunohistochemistry (IHC) 1+ or IHC 2+ and in situ hybridization \\[ISH\\]-negative, including FISH.\n\n* Biopsy proven primary malignancy or metastatic disease\n* At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment\n* Age 18 years or greater\n* ECOG performance of 0-2\n\nExclusion Criteria:\n\n* Creatinine \\> 2 times normal limit (obtained with 8 weeks of enrollment)\n* AST/ALT \\> 2 times normal limit (obtained with 8 weeks of enrollment)\n* Life expectancy \\< 3 months\n* Pregnancy or lactation\n* Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}